Obalon Announces Opening of Second Retail Treatment Center in Orange County, CA
February 20 2020 - 8:15AM
Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated
weight loss solutions company commercializing the first and only
FDA-approved swallowable, gas-filled intragastric balloon system
for the treatment of obesity, announces that it has opened its
second Company-managed retail treatment center.
“We are excited to have opened the second
Company-managed Obalon Center for Weight Loss™, further developing
our strategy to build a standardized, repeatable business using a
Company-owned or managed retail treatment center model,” said Bill
Plovanic, President and Chief Executive Officer of Obalon. “We
believe this new model will improve access to care for people with
obesity that are candidates for treatment with the Obalon Balloon
System.”
The Obalon Center for Weight Loss is staffed by a
separate professional corporation comprised of physicians and
registered dieticians to support a comprehensive weight loss
program. The program is centered on balloon treatment with the
Obalon Balloon System and includes additional services, such as 1:1
nutrition counseling with a registered dietitian to promote
sustainable weight loss focusing on behavior and lifestyle
modification, personalized goals and meal plans; and unlimited
access to on-demand video content, including meal plans, recipes,
and fitness classes. The Obalon Balloon System is FDA approved for
individuals with a BMI of 30 to 40, or who are approximately 30 to
100 pounds overweight.
The Company currently has two Company-managed
retail treatment centers in California with additional locations
expected to be opened in 2020. The first Obalon Center for Weight
Loss treatment center located in San Diego, CA was opened in
September 2019 and the Orange County, CA treatment center was
opened in February 2020. More information about Obalon Center for
Weight Loss treatment centers can be found by visiting:
www.obaloncenter.com.
About Obalon Therapeutics,
Inc.
Obalon Therapeutics, Inc. (NASDAQ: OBLN) is a San
Diego-based company focused on developing and commercializing novel
technologies for weight loss. For more information, please
visit http://www.obalon.com.
Cautionary Statement Regarding Forward
Looking Statements
This press release contains forward-looking
statements that are not purely historical regarding Obalon’s or its
management’s intentions, beliefs, expectations and strategies for
the future, including those related to new products and their
potential benefits. All forward-looking statements and reasons why
results might differ included in this press release are made as of
the date of this release, based on information currently available
to Obalon, deal with future events, are subject to various risks
and uncertainties, and actual results could differ materially from
those anticipated in those forward looking statements. The risks
and uncertainties that may cause actual results to differ
materially from Obalon’s current expectations are more fully
described in Obalon’s annual report on Form 10-K for the period
ended December 31, 2018, its quarterly report on Form 10-Q for the
period ended September 30, 2019 and its other reports, each as
filed with the Securities and Exchange Commission. Except as
required by law, Obalon assumes no obligation to update any such
forward-looking statement after the date of this press release,
except as required by law.
For Obalon Therapeutics, Inc.
Investor Contact: Bill Plovanic President and Chief
Executive Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103
wplovanic@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2023 to Apr 2024